Register
Login:
Share:
Email Facebook Twitter


Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold




Share Price Information for Salvarx Grp Plc (SALV)


Share Price: 10.50Bid: 9.00Ask: 12.00Change: 0.00 (0.00%)No Movement on Salvarx Grp Plc
Spread: 3.00Spread as %: 33.33%Open: 10.50High: 0.00Low: 0.00Yesterday’s Close: 10.50

Salvarx Group Plc Ord 2.5P

Salvarx Grp Plc is part of the Metals sector






Share Price SpacerPrice
10.50
Share Price SpacerBid
9.00
Share Price SpacerAsk
12.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
10.50
Share Price SpacerHigh
0.00
Share Price SpacerLow
0.00
Share Price SpacerClose
10.50
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX IM 36.70m £3.85m 10,000

52 Week High 93.00 52 Week High Date 19-DEC-2018
52 Week Low 8.00 52 Week Low Date 28-MAR-2019

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -2.100 -5.00 0.00 0.00


London South East Users info for Salvarx Grp Plc




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

18-Apr-19
08:16:37
10.30
9,767
Sell* 
9.00
12.00
1,006
Trade Type:
Ordinary

17-Apr-19
12:33:38
10.30
8
Sell* 
9.00
12.00
0.82
Trade Type:
Ordinary

16-Apr-19
12:03:10
11.85
8,388
Buy* 
9.00
12.00
993.98
Trade Type:
Ordinary




View more Salvarx Grp Plc trades >>

Directors Deals for Salvarx Grp Plc (SALV)
Trade DateActionNotifierPriceCurrencyAmountHolding
31-Oct-18Exercise of option
Trade Notifier Information for Salvarx Group
James (Jim) Mellon held the position of Non-Executive Director at Salvarx Group at the time of this trade.
 James (Jim) Mellon
23.2GBX86,23013406521
31-Oct-18Exercise of option
Trade Notifier Information for Salvarx Group
Gregory(Greg) Bailey held the position of Non-Executive Director at Salvarx Group at the time of this trade.
 Gregory(Greg) Bailey
23.2GBX86,23013406521
View more Salvarx Grp Plc directors dealings >>


kentan
Posts: 546
Opinion:No Opinion
Price:10.50
RE: Portage Biotech
Wed 19:05
Hi Barwickman,
Today I received my Portage Biotech share certificates (paper version) by post. If I wish to sell them I can deposit them with the registrars and give instructions to sell. Alternatively, I can hold onto them and keep them until I wish to sell.
I received my SALV number of shares multiplied by 18 to give the number of Portage shares.
The SALV shares are still in my ISA portfolio at the SP x number of shares (actually shows as a loss).

Therefore at today's closing price of 10.50p per SALV share and the $0.105 x 18 for each Portage share, calculated with the exchange rate to GBP .... each share combined is worth £1.485 ... a very nice profit on the original investment.

With exciting prospects for SALV with Intensity and Portage latest acquisition of the French company, I am inclined to stay for the ride and keep both shares.
FOUR.Ms
Posts: 48
Opinion:No Opinion
Price:10.50
RE: Portage Biotech
Wed 18:07
Looking good. Portage Biotech up 30% with the Intensity Therapeutics news.
barwickman
Posts: 455
Opinion:No Opinion
Price:10.00
RE: Portage Biotech
4 Apr '19
hi kentan are you saying Barclays are going to sell your portage share, don't you have a choice, spoke to iii and they said the shares are there I can see them but like you said cant trade them, they said they will do nothing with them until I chose to do so, I want to keep my portage shares for sure ,
kentan
Posts: 546
Opinion:No Opinion
Price:10.00
RE: Portage Biotech
4 Apr '19
As stated on my Barclays Smart Investor "Corporate Action" notice:
The terms are Shareholders who hold SalvaRX Shares on the scheme record date will retain their holding in SalvaRX and in addition to this will receive 18 demerger shares in the form of Portage Biotech Ltd shares for every SalvaRX share held. Once the demerger goes ahead you will retain your holding in SalvaRX.
ISA Clients Investors’ holdings will be registered to a holding statement which will be posted to the address we hold on file for you. A holding statement is a representation of your shares which are held electronically at the Registrars. We are in conversation with the Registrar to establish when our clients will receive their holding statements. We anticipate this could take approx 12 weeks and will update you once we have further information to share. Please be aware that, if you have an ISA, by registering the shares in your own name you will be removing the shares from the tax-efficient ISA wrapper. It is your responsibility to ensure you are aware of any tax implications.

As my holding in SALV is in an ISA:
If the shares are removed from your ISA, the value removed will allow you to reinstate this amount in full, in shares (Bed & ISA) from your Investment Account, or in cash for the tax year 2019/20.

Because Portage Biotech shares are traded on the Toronto, Canadian market in US $, it is likely they will be sold on your behalf and the funds raised will be credited to your account as cash. You will still have your holding for SALV, valued at whatever the share price (SP) is on the day.

I think the first day that Barclays can cash-in (by trading/selling the Portage stock) is July 9th 2019, when the definitive offer of 18 Portage Biotech shares for every 1 SALV share becomes finalised.

Hope this clarifies the situation with holdings held by Nominee Registrars.
Chazzy2
Posts: 709
Opinion:No Opinion
Price:10.00
Intensity therapeutics
3 Apr '19
have tweeted links to two very interesting Lew Bender interviews.
View more share chat for Salvarx Grp Plc (SALV) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk











Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.